An interventional study of active tDCS and Sham tDCS in Depression and Parkinson's, sponsored by Pacific Parkinson's Research Centre. Terminated at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-05-14.
Sponsored by Pacific Parkinson's Research Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 533 studies in Depression with a site in Canada — 107 open to participants now, 124 under way, 7 of them phase 3. Depression · Canada.
Among the 533 studies in Depression with a site in Canada, this one is the 479th largest by enrollment of the 488 interventional ones that give a count, is one of 17 that started in 2015, is one of 334 with no phase, and was the 161st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →107 of the 533 studies in Depression with a site in Canada are open now. Recruiting first, the newest first:
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Australia and 12 more countries
Ages 18–75
University of Regina · Sites in Canada
Ages 18+
University of Toronto · Sites in Canada
Ages 18+
Lakshmi N Yatham · Sites in Canada
Ages 19–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
533 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 55 · Phase 4 37
First in 1997; this study’s year is marked. 17 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 77 across the 488 interventional studies, 262 across the 45 observational. Of the 346 that completed or were terminated, 45 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 533 have an industry lead sponsor. The 10 most frequent:
Pacific Parkinson's Research Centre is the lead sponsor of 7 studies on the registry; none are open to participants now.
Pacific Parkinson's Research Centre has 1 study filed under Depression — fewer than ten, so there is no comparison to draw.
35 of the studies in Depression with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07313657Bruyère Health Research Institute.Improving Care and Mental Well-Being for Adults With Heart Failure | 2026-11-30 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT06745349University of ReginaThe Sleep Course: An Online Sleep Intervention for Adults With Self-reported Sleep Difficulties | 2026-12 |
Add all 35 to your calendar (.ics) → With an account.
Among the 533 studies in Depression with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is a progressive neurological disease that has effects on both movement and mental health. One of the most common mental health complications of PD is depression. Up to 30% of Parkinson's patients will experience depression at some point. We aim to investigate whether transcranial direct current stimulation (tDCS), a type of electrical stimulation for the brain, can improve depression in PD as well as improve motor function in PD.
The purpose of this double-blind, randomized control design study is to investigate the efficacy of 15-sessions of tDCS (versus 15-sessions of sham tDCS) to treat depression in PD. We will also assess dopamine function in a smaller cohort of participants before and after their 15 sessions of tDCS by using PET scanning.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria for PET:
Exclusion Criteria for MRI:
active tDCS will be used on half of the study participants
Device: active tDCS
Sham tDCS will be used on half of the study participants
Device: Sham tDCS
transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
HAMD score
an assessment of the severity of depression
Time frame: 12 weeks
Dopamine levels
PET scanning will be used to assess dopamine levels before and after sham/active tDCS in 20 participants
Time frame: 12 weeks
The record gives a start of Jan 2015, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pacific Parkinson's Research Centre